ABC | Volume 114, Nº5, Maio 2020

Posicionamento Posicionamento da Sociedade Brasileira de Cardiologia para Gravidez e Planejamento Familiar na Mulher Portadora de Cardiopatia – 2020 Arq Bras Cardiol. 2020; 114(5):849-942 200. Kilic ID, Tanriverdi H, Evrengul H, Uslu S, Sungur MA Left ventricular non- compaction in pregnancy. Cardiovasc J Afr. 2013;24(3):e1-2. 201. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12(8):767-78. 202. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012;485(7398):333-8. 203. BelloNA,AranyZ.Molecularmechanismsofperipartumcardiomyopathy:a vascular/hormonalhypothesis.TrendsCardiovascMed.2015;25(6):499-504. 204. Toescu V, Nuttall SL, Martin U, Kendall MJ, Dunne F. Oxidative stress and normal pregnancy. Clin Endocrinol (Oxf). 2002;57(5):609‑13. 205. Hilfiker‑Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, etal.AcathepsinD‑cleaved16kDa formofprolactinmediatespostpartum cardiomyopathy. Cell. 2007; 128(3):589‑600. 206. Hilfiker‑KleinerD,SliwaK,DrexlerH.Peripartumcardiomyopathy:Recent insights in its pathophysiology. Trends CardiovascMed. 2008;18(5):173‑9. 207. Halkein J, Tabruyn SP, Ricke-HochM, Haghikia A, NguyenNQ, Scherr M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest. 2013;123(5):2143-54. 208. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema JP, Becker A, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation. 2010;121(13):1465-73. Erratum in: Circulation. 2010;121(21):e425. 209. Hilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke A. Bromocriptine for the treatment of peripartumcardiomyopathy: a multicentre randomized study. Eur Heart J. 2017;38(35):2671-9. 210. de Jong JS, Rietveld K, van Lochem LT, Bouma BJ. Rapid left ventricular recovery after cabergoline treatment in a patient with peripartum cardiomyopathy. Eur J Heart Fail. 2009;11(2):220-2. 211. Melo MA, Carvalho JS, Feitosa FE, Araujo Júnior E, Peixoto AB, Costa Carvalho FH, et al. Peripartum Cardiomyopathy Treatment with Dopamine Agonist and Subsequent Pregnancy with a Satisfactory Outcome. Rev Bras Ginecol Obstet. 2016;38(6):308-13. 212. Bello N, Rendon ISH, Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review andmeta-analysis. J Am Coll Cardiol. 2013;62(18):1715-23. 213. McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, et al. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC Study (Investigations of PregnancyAssociated Cardiomyopathy). J Am Coll Cardiol. 2015;66(8):905-14. 214. SliwaK,Anthony J.Latemate rnaldeaths:aneglectedresponsibility.Lancet . 2016;387(10033):2072-3. 215. Vega CE, Soares VM, Nasr AM. Mortalidade materna tardia: comparação de dois comitês de mortalidade materna Não Brasil. Cad Saúde Pública. 2017;33(3):e00197315. 216. Kolte D, Khera S, Aronow WS, Palaniswamy C, Mujib M, Ahn C, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J AmHeart Assoc. 2014;3(3):e001056. 217. Goland S, Bitar F, Modi K, Safirstein J, Ro A, Mirocha J, et al. Evaluation of the Clinical Relevance of Baseline Left Ventricular Ejection Fraction as a Predictor of Recovery or Persistence of Severe Dysfunction in Women in the United States With Peripartum Cardiomyopathy. J Card Fail. 2011;17(5):426-30. 218. Hilfiker-Kleiner D, Haghikia A, Nonhoff J, Bauersachs J. Peripartum cardiomyopathy: current management and future perspectives. Eur Heart J. 2015;36(18):1090-7. 219. Bouabdallaoui N, Mouquet F, Lebreton G, Demondion P, Le Jemtel TH, Ennezat PV. Current knowledge and recent development onmanagement of peripartum cardiomyopathy. Eur Heart J Acute Cardiovasc Care. 2017;6(4):359-66. 220. Rasmusson K, Brunisholz K, Budge D, Horne BD, Alharethi R, Folsom J, et al. Peripartum cardiomyopathy: post-transplant outcomes from the United Network for Organ Sharing Database. J Heart Lung Transplant. 2012;31(2):180-6. 221. Sliwa K, Petrie MC, Hilfiker-Kleiner D, Mebazza A, Jackson A, Johnson MR, et al. Long-term proegnosis subsequent pregnancy contraception and overall management of peripartum cardiomyopathy. Eur J Heart Fail. 2018;20(6):951-62. 222. Bauersachs J, Konig T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, Mbakwem A, HamdanR, Jackson AM, Forsyth P, Boer AR, Mueller C, Lyon RA, Lund HL, Piepoli MF, Heymans S, CChioncel O, Anker D S, Ponikowski P, Seferovic P, Johnson MR, Mebazaa A, Sliwa K. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2019;21(9):827-843. 223. Sousa AGMR, Timerman A.Doença arterial coronária-Peculiaridades na mulher Reposição Hormonal. Cap.38.1ª edição-Atheneu 224. Gibson P, Narous M, Firoz T, Chou D, Barreix M, Say L, et al. Incidence of myocardial infarction in pregnancy: a systematic reviewandmeta-analysis of population-based studies. Eur Heart J Qual Care Clin Outcomes. 2017;3(3):198-207. 225. Elkayam U, Jalnapurkar S, Barakkat MN, Khatri N, Kealey AJ, Mehra A, et al. Pregnancy-Associated Acute Myocardial Infarction: A Review of Contemporary Experience in 150 Cases Between 2006 and 2011. Circulation. 2014;129(16):1695-702. 226. Hayes SH, KimESH, Saw J, AdlamD, Arslanian-EngorenC, Economy KE, et al. Spontaneous Coronary Artery Dissection: Current State of the Science: A Scientific Statement from the American Heart Association. Circulation. 2018;137(19):e523-57. 227. Garcia M, Mulvagh SL, Merz CN, Buring JE, Manson JE. Cardiovascular disease in women: clinical perspectives. Circ Res. 2016;118(8):1273-93. 228. Desoye G, Schweditsch MO, Pfeiffer KP, Zechner R, Kostner GM. Correlation of hormones with lipid and lipoprotein levels during normal pregnancy and postpartum. J Clin Endocrinol Metab. 1987;64(4):704-12. 229. Faludi AA, IzarMCO, Saraiva JFK, Chacra APM, BiancoHT, Afiune ANeto, et al. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017. Arq Bras Cardiol. 2017;109(2 Suppl 1):1-76. 230. Basar R, Uzum AK, Canbaz B, Dogansen SC, Kalayoglu-Besisik S, Altay- Dadin S, et al. Therapeutic apheresis for sever hypertriglyceridemia in pregnancy. Arch Gynecol Obstet. 2013;287(5):839-43. 231. Russi G. Severe dyslipidemia in pregnancy: The role of therapeutic apheresis. Transfus Apher Sci. 2015;53(3):283-7. 232. Wild R, Weedin EA, Wilson D. Dyslipidemia in pregnancy. Cardiol Clinic. 2015;33(2):209-15. 233. De Souza AW, de Carvalho JF. Diagnostic and classification criteria of Takayasu arteritis. J Autoimmun. 2014 Feb-Mar;48-49:79-83. 234. Kim ESH, Beckman J. Takayasu arteritis: challenges in diagnosis and management. Heart. 2018;104(7):558-65. 235. Machen L, Clowse ME. Vasculitis and Pregnancy. Rheum Dis Clin North Am. 2017;43(2):239-47. 936